000143980 001__ 143980
000143980 005__ 20240229112613.0
000143980 0247_ $$2doi$$a10.1080/0284186X.2018.1557341
000143980 0247_ $$2pmid$$apmid:30777496
000143980 0247_ $$2ISSN$$a0284-186X
000143980 0247_ $$2ISSN$$a1100-1704
000143980 0247_ $$2ISSN$$a1651-226X
000143980 0247_ $$2ISSN$$a1651-2499
000143980 0247_ $$2altmetric$$aaltmetric:56083880
000143980 037__ $$aDKFZ-2019-01537
000143980 041__ $$aeng
000143980 082__ $$a610
000143980 1001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b0$$eFirst author$$udkfz
000143980 245__ $$aReturn to work after cancer. A multi-regional population-based study from Germany.
000143980 260__ $$aAbingdon$$bTaylor & Francis Group$$c2019
000143980 3367_ $$2DRIVER$$aarticle
000143980 3367_ $$2DataCite$$aOutput Types/Journal article
000143980 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1565704925_29889
000143980 3367_ $$2BibTeX$$aARTICLE
000143980 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143980 3367_ $$00$$2EndNote$$aJournal Article
000143980 520__ $$aBackground: With improving prognosis, the ability to return to work after cancer has become a realistic goal but only little is known regarding details such as sustainability, financial consequences, and potential determinants of return to work in long-term survivors in Germany. Methods: We studied return to work in a population-based sample of 1558 long-term cancer survivors, diagnosed in 1994-2004 with breast, colorectal or prostate cancer before age 60 (mean 50.1). Information regarding employment status and financial difficulties was obtained via mailed questionnaires from patients who were identified by six population-based cancer registries in Germany. Cumulative incidence of return to work was determined by time-to-event analysis with consideration of competing events. Chi2 tests and multiple logistic regression modeling were employed to identify potential sociodemographic and clinical determinants of return to work. Results: Within a mean period since diagnosis of 8.3 years, 63% of all working-age cancer survivors initially returned to their old job and another 7% took up a new job. Seventeen percent were granted a disability pension, 6% were early retired (not cancer-related), 4% became unemployed, and 1% left the job market for other reasons. Resumption of work occurred within the first 2 years after diagnosis in 90% of all returnees. Cancer-related reduction of working hours was reported by 17% among all returnees and 6% quit their job due to cancer within 5 years past return to work. The probability of return to work was strongly related with age at diagnosis, tumor stage, education, and occupational class but did not differ with respect to the tumor site, gender nor marital status. Conclusions: Most long-term survivors after breast, colorectal, or prostate cancer of working-age are able to return to work. However, financial problems might arise due to a reduction in working hours. An additional provision of targeted interventions for high-risk groups should be discussed.
000143980 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143980 588__ $$aDataset connected to CrossRef, PubMed,
000143980 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b1$$udkfz
000143980 7001_ $$aBertram, Heike$$b2
000143980 7001_ $$00000-0003-4195-5236$$aEberle, Andrea$$b3
000143980 7001_ $$aHolleczek, Bernd$$b4
000143980 7001_ $$aPritzkuleit, Ron$$b5
000143980 7001_ $$aWaldeyer-Sauerland, Mechthild$$b6
000143980 7001_ $$00000-0002-5909-9936$$aWaldmann, Annika$$b7
000143980 7001_ $$00000-0002-0743-6128$$aZeissig, Sylke Ruth$$b8
000143980 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b9$$udkfz
000143980 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b10$$udkfz
000143980 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b11$$eLast author$$udkfz
000143980 773__ $$0PERI:(DE-600)1492623-4$$a10.1080/0284186X.2018.1557341$$gVol. 58, no. 5, p. 811 - 818$$n5$$p811 - 818$$tActa oncologica$$v58$$x0001-6926$$y2019
000143980 909CO $$ooai:inrepo02.dkfz.de:143980$$pVDB
000143980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143980 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000143980 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143980 9141_ $$y2019
000143980 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143980 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143980 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143980 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA ONCOL : 2017
000143980 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143980 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143980 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143980 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143980 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143980 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143980 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143980 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143980 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143980 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143980 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000143980 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lCancer Survivorship$$x1
000143980 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000143980 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x3
000143980 980__ $$ajournal
000143980 980__ $$aVDB
000143980 980__ $$aI:(DE-He78)C070-20160331
000143980 980__ $$aI:(DE-He78)C071-20160331
000143980 980__ $$aI:(DE-He78)L101-20160331
000143980 980__ $$aI:(DE-He78)C120-20160331
000143980 980__ $$aUNRESTRICTED